This podcast interviews Karl Thiel about the booming market for GLP-1 weight-loss drugs like Ozempic and Mounjaro. The discussion covers the drugs' mechanisms, material differences between various GLP-1 drugs (e.g., semaglutide vs. terzepatide), concerns regarding side effects and their prevalence, and the implications of upcoming patent expirations for companies like Eli Lilly and Novo Nordisk. Thiel also addresses the role of compounding pharmacies and the potential impact on companies like Hims & Hers, as well as the lack of data on the drugs' effects on individuals with eating disorders. Investors are advised to consider a basket approach, diversifying investments across several pharmaceutical companies rather than focusing solely on Lilly or Novo Nordisk due to market uncertainties.
